Why Aveo Pharmaceuticals Shares Plunged

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of cancer therapeutics company Aveo Pharmaceuticals (NASDAQ: AVEO  ) sank 10% today after the final overall survival results of its kidney cancer drug tivozanib disappointed Wall Street.

So what: Results from the phase 3 study showed a median overall survival rate of 28.8 months for tivozanib versus a median of 29.3 months for Onyx Pharmaceutical's (UNKNOWN: ONXX.DL  ) Nexavar, reinforcing concerns over tivozanib's risks relative to competing treatments. While the greater risk of death was not statistically significant, analysts are worried that tivozanib simply isn't special enough to stand out in an increasingly crowded space.

Now what: Tivozanib is currently under FDA review, and an approval decision is expected by July 28.

"We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO-1, receiving the FDA's acceptance of the NDA submission and expanding tivozanib clinical development into patients with triple negative breast cancer," said President and CEO Tuan Ha-Ngoc.

So while Aveo remains just too speculative for average Fools, today's double-digit drop -- the stock is now off about 50% from its 52-week high -- might be an attractive opportunity for biotech-savvy contrarians.

While you can certainly make huge gains in biotech stocks, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Interested in more info Aveo? Add it to your watchlist.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2253190, ~/Articles/ArticleHandler.aspx, 9/19/2014 11:57:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement